Arena Pharmaceuticals Aktie - Fundamentalanalyse - Dividendenrendite KGV

Arena Pharmaceuticals (ISIN: US0400471027, WKN: 939027) Kursdatum: 18.05.2018 Kurs: 45,530 USD
Beschreibung Daten
Symbol ARNA
Marktkapitalisierung 1.787.507.840,00 USD
Land Vereinigte Staaten von Amerika
Indizes NASDAQ Comp.
Sektor Pharma
Rohdaten nach US GAAP in Millionen USD
Aktiensplits 2017-06-19 - 1.0000/10.0000 |
Internet www.arenapharm.com
Letztes Bilanz Update 15.03.2018

Fundamentaldaten

Fundamental Verhältnisse errechnet am: 18.05.2018
KFCV KCV DIV Rendite GKR EKQ KGV KUV KBV
-26,78 -26,82 0,00% -32,05 61,05 -16,44 83,78 8,63

Firmenbeschreibung

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. Its proprietary investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod that is in Phase II trials for treating immune and inflammatory conditions with primary focus on ulcerative colitis and hepatic conditions, as well as for primary biliary cholangitis and pyoderma gangrenosum; and APD371, which is in Phase II trial for the treatment of pain associated with Crohn\'s disease. The company has collaboration agreements with Everest Medicines Limited; Axovant Sciences GmbH; Boehringer Ingelheim International GmbH; Eisai Co., Ltd.; and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.

Die Finanzoo GmbH übernimmt keine Haftung für die Richtigkeit der Angaben! Alle Angaben sind ohne Gewähr. Quellen: www.bundesanzeiger.de, www.sec.gov, www.arenapharm.com